Experimental and investigational · Research guide

Rapamycin for dogs: serious longevity science, still an unanswered clinical question

What the early cardiac studies, safety observations and TRIAD trial do—and do not—establish for an ageing dog.

The takeaway

Nara’s take.

Rapamycin is one of the most important drugs being studied in canine ageing. That makes the trials worth following closely, not the answer settled. Published small dog studies do not yet establish a lifespan benefit.

How it may work

Why mTOR is an ageing target

Rapamycin influences mTOR signalling, a system that helps cells respond to nutrients and regulate growth and maintenance. Its effects in laboratory ageing research provide a biological reason to investigate whether carefully controlled exposure can benefit older companion dogs.

The same pathway has many normal jobs. The question is not whether turning it down is universally good, but whether a particular regimen creates a net benefit in a particular population. Mechanism cannot choose the dose or remove the need to measure harm.

Sources: [1], [2]

What the research shows

The early dog studies do not all point the same way

A short randomized study in 24 middle-aged dogs reported favourable changes in selected cardiac measures. A later masked placebo-controlled study in 17 healthy client-owned dogs used a different, lower-dose regimen over six months and did not find significant echocardiographic benefit.

Those studies help define questions and feasibility, but neither establishes that dogs live longer. Differences in regimen, sample size and follow-up make it inappropriate to treat the earlier positive signal as definitive or the later null result as the final word on canine longevity.

Sources: [1], [3]

What the research shows

Safety observations and the larger trial matter

A published case described severe, initially asymptomatic hypertriglyceridaemia during long-term low-dose rapamycin exposure. One case cannot estimate how often this occurs, but it is a reason not to equate an apparently well dog with an absence of adverse effects.

TRIAD was designed as a larger randomized, masked, placebo-controlled study of rapamycin in middle-aged dogs. The linked study-design paper explains what the researchers intend to test; it is not a report of successful lifespan extension. This editorial review did not verify a completed TRIAD lifespan result.

Sources: [4], [2]

Nara's practical guidance

What this means for your dog

Nara considers this a clinical-research decision, not a routine addition to a home longevity stack. Eligibility, existing disease, other medicines, laboratory monitoring and the exact regimen all matter. A trial may help future dogs without guaranteeing benefit to the participating dog.

The commitment includes visits and monitoring, not just tablets. This guide does not provide a dose or advise obtaining rapamycin for unsupervised use. A reproducible improvement in survival or meaningful healthspan, weighed against adverse outcomes in diverse pet dogs, would be the result that changes the decision.

Evidence informing this guidance: [3], [4], [2]

Follow the evidence

Sources and review notes.

Primary studies, clinical guidance and explicitly labelled sponsor disclosures. A mechanism, an observational association and a treatment result are different kinds of evidence.

Editorial research update: 2026-09-24. These guides build on Nara’s existing source records and a fresh check of accessible primary abstracts, full texts and official pages. This is not an exhaustive systematic review or a new independent clinical review. The evidence assessment retains its own date and status. Practical examples are Nara’s interpretation, not validated treatment protocols.

[1] 2017 · Dog · Randomized controlled canine intervention trial
A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs
Urfer SR, Kaeberlein TL, Mailheau S, Bergman PJ, Creevy KE, Promislow DEL, Kaeberlein M. GeroScience.
10.1007/s11357-017-9972-z
Short-term intermittent rapamycin study reporting favorable cardiac changes and short-term tolerability.
[2] 2025 · Dog · Randomized clinical trial design/protocol
Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project
Coleman AE et al.; Dog Aging Project Consortium. GeroScience.
10.1007/s11357-024-01484-7
Defines the ongoing trial intended to test canine healthspan and lifespan; it is design evidence, not an efficacy result.
[3] 2023 · Dog · Masked randomized placebo-controlled canine intervention trial
A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs
Barnett BG, Wesselowski SR, Gordon SG, Saunders AB, Promislow DEL, Schwartz SM, Chou L, Evans JB, Kaeberlein M, Creevy KE. Frontiers in Veterinary Science.
10.3389/fvets.2023.1168711
Longer lower-dose rapamycin study finding no significant echocardiographic benefit and providing six-month safety data.
[4] 2023 · Dog · Canine adverse-event case report
Case report: Severe asymptomatic hypertriglyceridemia associated with long-term low-dose rapamycin administration in a healthy middle-aged Labrador retriever
Evans JB, Chou L, Kaeberlein M, Promislow DEL, Creevy KE. Frontiers in Veterinary Science.
10.3389/fvets.2023.1285498
Important safety signal arising during the six-month rapamycin trial.

Keep reading

Connected questions.

LOY-002

An investigational senior-dog longevity candidate.

Senolytics

Clearing senescent cells — a strong mechanism with thin canine data.

Preventive care

Screening cadence, early detection, and baseline diagnostics before decline is visible.

Open Nara’s evidence assessment

The guide above explains the topic. This separate record preserves the accepted claim, confidence, limitations and safety context. Publishing an article does not upgrade the science or turn an experimental intervention into a recommendation.

Nara’s evidence view

Clinical-trial context only

Insufficient or conflictingCanine functional outcomesLow confidence

The claim we’re evaluating

Intermittent low-dose rapamycin has sufficient canine geroscience evidence to justify continued investigation, but available trials do not demonstrate improved canine healthspan or lifespan and provide inconsistent evidence for cardiac benefit across regimens.

Nara’s interpretation

Rapamycin has unusually strong geroscience plausibility and more direct canine evidence than most experimental longevity drugs, but the canine results are not equivalent to a longevity result. A short trial reported favorable cardiac changes whereas a longer lower-dose trial did not reproduce a significant echocardiographic benefit. Until TRIAD or comparable trials report healthspan and survival outcomes, Nara should not say that rapamycin makes dogs live longer.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

How we reached this view

What the evidence shows

A 2017 randomized trial in 24 healthy middle-aged companion dogs reported favorable changes in several echocardiographic measures after 10 weeks of intermittent rapamycin at 0.05 or 0.1 mg/kg three times weekly, with no overt clinical toxicity. A later masked randomized trial in 17 healthy dogs used 0.025 mg/kg three times weekly for six months and found no statistically significant echocardiographic difference at six or twelve months. A severe reversible hypertriglyceridemia case occurred in a treated dog. TRIAD is designed around aging, healthspan, and lifespan endpoints; its published protocol shows those questions are being tested, not answered.

Important limitations

The two completed healthy-dog randomized trials were very small and used materially different dose, cumulative exposure, and treatment duration.
The favorable cardiac signal in the first trial was not reproduced at statistical significance in the longer lower-dose study.
Echocardiographic changes are not equivalent to lower disease burden, improved healthspan, or longer lifespan.
Available safety datasets are too small to characterize uncommon adverse events or long-term risk reliably.

What would change Nara’s view

What would strengthen our view

A prespecified TRIAD analysis or another adequately powered randomized trial showing improvement in validated canine healthspan endpoints.
A statistically and clinically meaningful survival benefit in a randomized companion-dog trial.
Larger longitudinal safety datasets defining the frequency and significance of metabolic, hematologic, infectious, and other adverse effects.

What could weaken our view

TRIAD or another adequately powered study finding no meaningful difference in healthspan or survival.
Failure to reproduce claimed functional benefits at clinically relevant regimens.
A higher-than-expected rate of serious metabolic, immunologic, infectious, or other adverse outcomes.

What could change our position

Replicated improvement in meaningful canine healthspan with acceptable safety could move rapamycin toward veterinary_or_clinical_context.
Randomized evidence of longer canine lifespan with maintained function would justify a major upgrade in the longevity assessment.
A definitive null lifespan/healthspan trial combined with unfavorable adverse effects could move the position toward not_currently_supported or potential_concern.

Safety and clinical context

Safety is regimen-dependent; low-dose intermittent findings should not be generalized to other exposures.
The six-month randomized study was reassuring at the group level but too small to exclude uncommon toxicity.
Severe reversible hypertriglyceridemia has been documented in a treated companion dog.
Rapamycin is a pharmacologically active prescription drug, not an owner-directed supplement strategy.

Evidence record

Nara position: Clinical-trial context only
Evidence maturity: Insufficient or conflicting
Most direct relevant evidence: Canine functional outcomes
Overall confidence: Low confidence
Evidence reviewed through: 2026-08-12
Assessment date: 2026-08-12
Review status: Initial Nara internal evidence assessment
Framework: Nara Evidence Framework v1.0

How Nara evaluates science

Anchor sources

A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs

GeroScience · 2017 · Dog

Randomized controlled canine intervention trial

Short-term intermittent rapamycin study reporting favorable cardiac changes and short-term tolerability.

10.1007/s11357-017-9972-z

A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs

Frontiers in Veterinary Science · 2023 · Dog

Masked randomized placebo-controlled canine intervention trial

Longer lower-dose rapamycin study finding no significant echocardiographic benefit and providing six-month safety data.

10.3389/fvets.2023.1168711

Case report: Severe asymptomatic hypertriglyceridemia associated with long-term low-dose rapamycin administration in a healthy middle-aged Labrador retriever

Frontiers in Veterinary Science · 2023 · Dog

Canine adverse-event case report

Important safety signal arising during the six-month rapamycin trial.

10.3389/fvets.2023.1285498

Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project

GeroScience · 2025 · Dog

Randomized clinical trial design/protocol

Defines the ongoing trial intended to test canine healthspan and lifespan; it is design evidence, not an efficacy result.

10.1007/s11357-024-01484-7

Your dog’s context

Bring this back to your dog.

Loading your dog’s context…